Aegis Capital Believes Valeant Pharmaceuticals' Bid For Allergan Is Looking More Promising
July 02, 2014 at 10:29 AM EDT
In a report published Wednesday, Aegis Capital Corp. analyst Raghuram Selvaraju reiterated a Buy rating and $180.00 price target on ...
